Results 241 to 250 of about 618,690 (430)

Expert Perspective: How, When, and Why to Potentially Stop Antiresorptive Drugs in Osteoporosis

Arthritis &Rheumatology, EarlyView.
Osteoporosis is a chronic disease, and antiresorptive treatments are often continued for many years. Despite their established efficacy in reducing fracture risk, the most commonly used antiresorptive treatments, bisphosphonates and denosumab, have short‐ and long‐term risks that, coupled with their benefits and other unique characteristics, influence ...
Giovanni Adami, Kenneth G. Saag
wiley   +1 more source

Continuous renal replacement therapy for acute kidney injury: a case report. [PDF]

Transl Pediatr
Wang J, Bao Y, Guan L, Tan L.
europepmc   +1 more source

Fabry Disease (α-Galactosidase A Deficiency): Renal Involvement and Enzyme Replacement Therapy [PDF]

, 2001
Robert J. Desnick, Melissa Wasserstein, Maryam Banikazemi   +2 more
openalex   +1 more source

Continuous Renal Replacement Therapy: Who, When, Why, and How

Chest, 2019
S. Tandukar, P. Palevsky
semanticscholar   +1 more source

Expert Perspectives on a Clinical Challenge: Hematologic Malignancies and Vasculitis

Arthritis &Rheumatology, Accepted Article.
Systemic vasculitis describes a collection of rare diseases each caused by inflammation of blood vessel walls that can cause severe systemic complications [[3, 4]](#ref‐0003). The pattern of vascular inflammation and resultant damage is frequently variable and may be mimicked, or directly triggered, by infection or malignancy.
Michelle L. Robinette, Hetty E. Carraway
wiley   +1 more source

Outcomes of Kidney Transplantation From Donors on Renal Replacement Therapy. [PDF]

Transplant Direct
Goussous N, Alghannam K, Than PA, Wang AX, Chen LX, Alexopoulos SP, Sageshima J, Perez RV.   +7 more
europepmc   +1 more source

A Microdomain-Structured Synthetic High-Flux Hollow-Fiber Membrane for Renal Replacement Therapy

, 2000
Nicholas A. Hoenich, S Stamp, Sarah J. Roberts   +2 more
openalex   +1 more source

Trends in post-operative mortality in patients requiring renal replacement therapy following cardiothoracic transplantation [PDF]

, 2001
Marlies Ostermann, R Chang, Laurie Reynolds, Andrew J. Murday, Brendan Madden, Stephen Nelson   +5 more
openalex   +1 more source

Mucosal‐associated invariant T cells in rheumatic diseases.

Arthritis &Rheumatology, Accepted Article.
Mucosal‐associated invariant T (MAIT) cells are innate‐like T cells defined by their semi‐invariant T cell receptor (TCR) and restriction by the MHC class I‐related molecule (MR1). These cells are primarily activated by microbial‐derived metabolites presented by MR1 or by cytokines. Upon activation, MAIT cells rapidly produce pro‐inflammatory cytokines,
Manon Lesturgie‐Talarek, Virginie Gonzalez, Lucie Beaudoin, Noémie Sénot, Corinne Miceli‐Richard, Yannick Allanore, Agnès Lehuen, Jerôme Avouac   +7 more
wiley   +1 more source

Continuous renal replacement therapy for severe transient hyperammonemia in a preterm infant weighing 1120 g: A case report. [PDF]

J Int Med Res
Xu J, Liu J, Yang H, Zhang W, Chen D, Liu Z.   +5 more
europepmc   +1 more source